首页> 外文OA文献 >Linking existing in vitro dermal absorption data to physicochemical properties: Contribution to the design of a weight-of-evidence approach for the safety evaluation of cosmetic ingredients with low dermal bioavailability.
【2h】

Linking existing in vitro dermal absorption data to physicochemical properties: Contribution to the design of a weight-of-evidence approach for the safety evaluation of cosmetic ingredients with low dermal bioavailability.

机译:将现有的体外皮肤吸收数据与理化特性联系起来:有助于设计一种证据权重方法,以评估皮肤生物利用度低的化妆品成分的安全性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To characterize the risk of cosmetic ingredients when threshold toxicity is assumed, often the "margin of safety" (MoS) is calculated. This uncertainty factor is based on the systemic no observable (adverse) effect level (NO(A)EL) which can be derived from in vivo repeated dose toxicity studies. As in vivo studies for the purpose of the cosmetic legislation are no longer allowed in Europe and a validated in vitro alternative is not yet available, it is no longer possible to derive a NO(A)EL value for a new cosmetic ingredient. Alternatively, cosmetic ingredients with a low dermal bioavailability might not need repeated dose data, as internal exposure will be minimal and systemic toxicity might not be an issue. This study shows the possibility of identifying compounds suspected to have a low dermal bioavailability based on their physicochemical properties (molecular weight, melting point, topological polar surface area and log P) and their in vitro dermal absorption data. Although performed on a limited number of compounds, the study suggests a strategic opportunity to support the safety assessor's reasoning to omit a MoS calculation and to focus more on local toxicity and mutagenicity/genotoxicity for ingredients for which limited systemic exposure is to be expected.
机译:为了在假定阈值毒性的情况下表征化妆品成分的风险,通常会计算“安全裕度”(MoS)。此不确定性因素基于全身无可观察到的(不良)效应水平(NO(A)EL),该水平可从体内重复剂量毒性研究得出。由于在欧洲不再允许以化妆品法规为目的的体内研究,并且尚无经过体外验证的替代品,因此不再可能得出新化妆品成分的NO(A)EL值。另外,具有低皮肤生物利用度的化妆品成分可能不需要重复的剂量数据,因为内部暴露量很小,全身毒性可能不是问题。这项研究表明,根据其理化特性(分子量,熔点,拓扑极性表面积和log P)及其体外皮肤吸收数据,可以鉴定出怀疑具有较低皮肤生物利用度的化合物。尽管仅对有限数量的化合物进行了研究,但该研究提出了一个战略机遇,可以支持安全评估人员的推理,以省去MoS计算,而将更多注意力集中在预期会受到有限的全身暴露的成分的局部毒性和诱变性/遗传毒性上。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号